🔴 Moderna is trading 4.3% down in pre-market as investors take profits after cancer-vaccine rally

Moderna is trading 4.28% down now at $143.25 as investors continue taking profits following the extraordinary cancer-vaccine rally.

• Recent coverage attributes the pullback to valuation concerns as the stock retraces after positive Phase 3 melanoma-vaccine results announced by Moderna and Merck.
• The Nasdaq Composite is up 1.10% pre-market, suggesting the decline is primarily stock-specific.
• No new August 27 company announcement was identified.